Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.

This study examined sociodemographic factors, cisplatin-related adverse health outcomes (AHOs), and cumulative burden of morbidity (CBMPt) scores associated with medication use for anxiety and/or depression in testicular cancer survivors (TCS).

A total of 1,802 TCS who completed cisplatin-based chemotherapy {greater than or equal to}12 months previously completed questionnaires regarding sociodemographic features and cisplatin-related AHOs (hearing impairment, tinnitus, peripheral sensory neuropathy (PSN), kidney disease). A CBMPt score encompassed the number and severity of cisplatin-related AHOs. Multivariable logistic regression models assessed the relationship of individual AHOs and CBMPt with medication use for anxiety and/or depression.

A total of 151 TCS (8.4%) used medications for anxiety and/or depression. No cisplatin-related AHO were reported by 511 (28.4%) participants, whereas 622 (34.5%), 334 (18.5%), 287 (15.9%), and 48 (2.7%), respectively had very low, low, medium, and high CBMPt scores. In the multivariable model, higher CBMPt scores were significantly associated with medication use for anxiety and/or depression (P<0.0001). Additionally, tinnitus (P=0.0009), PSN (P=0.02), and having health insurance (P=0.05) were significantly associated with greater use of these medications; whereas being employed (P=0.0005) and vigorous physical activity (P=0.01) were significantly associated with diminished use.

TCS with higher CBMPt scores had a higher probability of using medications for anxiety and/or depression and conversely, those who were employed and physically active tended to have reduced use of these medications.

Healthcare providers should encourage TCS to increase physical activity to improve both physical and mental health. Rehabilitation programs should assess work-related skills and provide career development counseling/training.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2021 Apr 13 [Epub ahead of print]

Shirin ArdeshirRouhaniFard, Paul C Dinh, Patrick O Monahan, Sophie D Fossa, Robert Huddart, Chunkit Fung, Yiqing Song, Darren R Feldman, Robert J Hamilton, David J Vaughn, Neil E Martin, Christian Kollmannsberger, Lawrence Einhorn, Kurt Kroenke, Lois B Travis

Indiana University – Purdue University Indianapolis., National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital., Department of Academic Radiotherapy and Oncology, Institute of Cancer Research and Royal Marsden Hospitals NHS Foundation Trust., Medicine, University of Rochester., Medicine, Memorial Sloan Kettering Cancer Center., Department of Surgery, Princess Margaret Cancer Center, University of Toronto., Hematology-Oncology, University of Pennsylvania., Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital., Medical Oncology, BC Cancer - Vancouver Centre., Regenstrief Institute., Indiana University – Purdue University Indianapolis .